From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer
Current Treatment Options in Oncology · 2024-12 · 25 (12) · 1580-1593
DOI: 10.1007/s11864-024-01282-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 26.11.2024. Verfasst von Xinyi Ding und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Precision Medicine, Biomarkers, Tumor. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: The National Natural Science Foundation of China, Changzhou social development science and technology support project, Jiangsu Funding Program for Excellent Postdoctoral Talent.
Abstract (Originalsprache)
OPINION STATEMENT: The biological heterogeneity of colorectal cancer makes its molecular characteristics essential for therapeutic decision-making and prognostic evaluation. Recent advancements in consensus molecular subtyping, based on gene expression profiling, have provided deeper insights into the heterogeneity of CRC. CMS1, known as the immune subtype, is characterized by robust immune activity and microsatellite instability. CMS2, the canonical subtype, exhibits significant activation of the WNT and MYC signaling pathways. CMS3, the metabolic subtype, features unique metabolic dysregulations. CMS4, the mesenchymal subtype, is recognized for its stromal invasion and angiogenesis, which are associated with a poorer prognosis. This review delivers a thorough analysis of the biological and clinical responses of each CMS subtype in colorectal cancer, highlighting their therapeutic vulnerabilities. It integrates data and clinical trial results to suggest potential new therapies for each subtype. The goal is to improve therapeutic efficacy, minimize treatment disparities, and offer CRC patients more precise treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China.
- Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
- Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
- Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China. jiangjingting@suda.edu.cn.
- Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China. jiangjingting@suda.edu.cn.
- Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China. jiangjingting@suda.edu.cn.
Förderung
- The National Natural Science Foundation of China
- Changzhou social development science and technology support project
- Jiangsu Funding Program for Excellent Postdoctoral Talent
- the Key R&D Project of Jiangsu Province
Zitieren
APA
Ding, X., Huang, H., Fang, Z., & Jiang, J. (2024). From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer. Current Treatment Options in Oncology, 25(12), 1580-1593. https://doi.org/10.1007/s11864-024-01282-5
Vancouver
Ding X, Huang H, Fang Z, Jiang J. From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer. Current Treatment Options in Oncology. 2024;25(12):1580-1593. doi:10.1007/s11864-024-01282-5
BibTeX
@article{Ding2024,
author = {Ding, Xinyi and Huang, Hao and Fang, Zhang and Jiang, Jingting},
title = {From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer},
journal = {Current Treatment Options in Oncology},
year = {2024},
volume = {25},
number = {12},
pages = {1580--1593},
doi = {10.1007/s11864-024-01282-5}
}
EUVIMED